Recent developments in fluoroquinolone phototoxicity

Photodermatology Photoimmunology and Photomedicine

Volumn 15, Issue 1, 1999, Pages 32-33

  Man, I ^a   Traynor, N J ^a   Ferguson, J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Fluoroquinolone antitiotics; Phototoxicity

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMIODARONE; CIPROFLOXACIN; LOMEFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THIAZIDE DIURETIC AGENT;

DRUG INDUCED DISEASE; HUMAN; PHOTOSENSITIVITY; PHOTOSENSITIZATION; PHOTOTOXICITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SUNBURN;

EID: 0032910213     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0781.1999.tb00050.x     Document Type: Review

References (17)

1. 4-oxide group in the phototoxicity of chlordiazepoxide in the rat. Photodermatol 1985: 2: 205-212.
2. Phillips G, Johnson BE, Ferguson J. The loss of antibiotic activity of ciprofloxacin by photodegradation. J Antimicrob Chemother 1990: 26: 783-789.
3. Johnson BE, Gibbs NK, Ferguson J. Quinolone antibiotic with potential to photosensitize skin tumorigenesis. J Photochem Photobiol B: Biol 1997: 37: 171-173.
4. Klecak G, Urbach F, Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol B: Biol 1997: 37: 174-181.
5. Ferguson J. Fluoroquinolone photosensitization: a review of clinical and laboratory studies. Photochem Photobiol 1995: 62: 954-958.
6. Jensen T, Pedersen SS, Nielsen CH, Hoiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 1987: 20: 585-594.
7. Ferguson J, Johnson BE. Clinical and laboratory studies of the photosensitizing potential of norfloxacin, a 4-quinolone broad-spectrum antibiotic. Br J Dermatol 1993: 128: 285-295.
8. Scheife RT, Cramer WR, Decker EL. Photosensitizing potential of ofloxacin. Int J Dermatol 1993: 32: 413-416.
9. Lopitaux R, Hermet R, Sirot J, Filiu P, Terver S. Tolerance de la perfloxacine au-course du traitement d'une serie d'infections osteoarticulaires. Therapie 1985: 40: 349-352.
10. Food and Drug Administration. FDA Committee urges strong warnings on Searle's maxaquin. Script 1810 1993: 32-33 (editorial).
11. Young AR, Fakouhi TD, Roniker B et al. Wavelength dependence of skin photosensitization by lomefloxacin. Photochem Photobiol 1994: 59 (suppl): 605.
12. Mitzutani K, Tokuta Y, Iwamoto Y, Takigawa M. Photosensitivity dermatitis induced by sparfloxacin. Rinshoy-Hifuki 1995: 49: 113-118.
13. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxain. Antimicrob Agents Chemother 1989: 33: 1778-1782.
14. Martinez LJ, Sik RH, Chignell CF. Fluoroquinolone antimicrobials: singlet oxygen, superoxide and phototoxicity. Photochem Photobiol 1998: 67: 399-403.
15. Tiefenbacher E, Haen E, Przybilla B, Kurz H. Photodegradation of some quinolones used as antimicrobial therapeutics. J Pharm Sci 1994: 83: 463-467.
16. Johnson BE, Gibbs NK, Ferguson J. The initial investigations on quinolone photosensitised skin tumorigenesis. Photoderm Photoimmunol Photomed 1995: 11: 236.
17. Reavy HJ, Traynor NJ, Gibbs NK. Photogenotoxicity of skin phototumorigenic fluoroquinolone antibiotics detected using the comet assay. Photochem Photobiol 1997: 66: 368-373.